medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-3-80-83medsovet-1755Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYКЛИНИЧЕСКИЙ СЛУЧАЙ НАБЛЮДЕНИЯ ПАЦИЕНТКИ С ОЖИРЕНИЕМ И СУБКЛИНИЧЕСКИМ ГИПОТИРЕОЗОМ НА ФОНЕ ЛЕЧЕНИЯ СИБУТРАМИНОМ И ЛЕВОТИРОКСИНОМ НАТРИЯCLINICAL FOLLOW-UP OF A PATIENT WITH OBESITY AND SUBCLINICAL HYPOTHYROIDISM DURING TREATMENT WITH SIBUTRAMINE AND LEVOTHYROXINE SODIUMТрошинаЕ. А.TroshinaE. A.

д.м.н., профессор, чл.-корр. РАН, 

Москва

MD, Prof., corresponding member of the RAS, 

Moscow

ГалиеваМ. О.GalievaM. O.

Москва

Moscow

МихинаМ. С.MikhinaM. S.

Москва

Moscow

МазуринаН. В.MazurinaN. V.

к.м.н.,

Москва

PhD in Medicine,

Moscow

Эндокринологический научный центр Минздрава РоссииРоссияEndocrinology Research Center, MoH RFRussian Federation201730122017038083Copyright © Трошина Е.А., Галиева М.О., Михина М.С., Мазурина Н.В., 20172017Трошина Е.А., Галиева М.О., Михина М.С., Мазурина Н.В.Troshina E.A., Galieva M.O., Mikhina M.S., Mazurina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1755

Среди коморбидных заболеваний ожирения наиболее частой эндокринопатией является гипотиреоз. В основе патогенеза обоих заболеваний лежит серотонинергическая недостаточность. В статье представлен клинический случай пациентки с ожирением и субклиническим гипотиреозом, всестороннее обследование которой позволило подобрать эффективную и безопасную патогенетическую терапию.

Among comorbidities of obesity, hypothyroidism is the most common endocrinopathy. The pathogenesis of both diseases is based on serotonin deficiency. The article tells about a clinical case of a patient with obesity and subclinical hypothyroidism; a comprehensive examination allowed to choose the efficient and safe pathogenetic therapy.

ожирениегипотиреозсибутраминмасс-спектрометрияobesityhypothyroidismsibutraminemass spectrometryReferencesYeo G, Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci, 2012, 15(10): 1343-1349. doi: 10.1038/nn.3211.Yeo G, Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci, 2012, 15(10): 1343-1349. doi: 10.1038/nn.3211.Galieva MO, Troshina EA, Mazurina NV, et al. The role of genetic factors in predicting results of obesity treatment with sibutramine – serotonin-norepinephrine reuptake inhibitor. Obesity and metabolism, 2016, 13(4): 21-26. doi: 10.14341/OMET2016421-26.Galieva MO, Troshina EA, Mazurina NV, et al. The role of genetic factors in predicting results of obesity treatment with sibutramine – serotonin-norepinephrine reuptake inhibitor. Obesity and metabolism, 2016, 13(4): 21-26. doi: 10.14341/OMET2016421-26.Zamponi GW, Currie KP. Regulation of CaV 2 calcium channels by G protein coupled receptors. Biochim Biophys Acta, 2013, 1828: 1629-1643. doi: 10.1016/j.bbamem.2012.10.004.Zamponi GW, Currie KP. Regulation of CaV 2 calcium channels by G protein coupled receptors. Biochim Biophys Acta, 2013, 1828: 1629-1643. doi: 10.1016/j.bbamem.2012.10.004.Chung KY, Rasmussen SG, Liu T, Li S, DeVree BT, Chae PS et al. Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor. Nature, 2011, 477: 611-615. doi: 10.1038/nature10488.Chung KY, Rasmussen SG, Liu T, Li S, DeVree BT, Chae PS et al. Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor. Nature, 2011, 477: 611-615. doi: 10.1038/nature10488.Лычкова А.Э. Нервная регуляция функции щитовидной железы. Вестник РАМН. 2013, 6: 49-55.Лычкова А.Э. Нервная регуляция функции щитовидной железы. Вестник РАМН. 2013, 6: 49-55.Broedel O, Eravci M, Fuxius S, Smolarz T, Jeitner A, Grau H, Stoltenburg-Didinger G, Plueckhan H, Meinhold H, Baumgartner A. Effects of hyperand hypothyroidism on thyroid hormone concentrations in regions of the rat brain. Am. J. Physiol. Endocrinol. Metab., 2003, 285(3): 470-480.Broedel O, Eravci M, Fuxius S, Smolarz T, Jeitner A, Grau H, Stoltenburg-Didinger G, Plueckhan H, Meinhold H, Baumgartner A. Effects of hyperand hypothyroidism on thyroid hormone concentrations in regions of the rat brain. Am. J. Physiol. Endocrinol. Metab., 2003, 285(3): 470-480.Тejani-Butt SM, Yang J, Kaviani A. Time course of altered thyroid states on 5-НТ1A receptors and 5-НТ uptake sites in rat brain: An autoradiographic analysis. Neuroendocrinology, 1993, 57: 1011-1018.Тejani-Butt SM, Yang J, Kaviani A. Time course of altered thyroid states on 5-НТ1A receptors and 5-НТ uptake sites in rat brain: An autoradiographic analysis. Neuroendocrinology, 1993, 57: 1011-1018.Heal DJ, Smith SL. The effects of acute and repeated administration of T3 to mice on 5-HТ1 and 5-НТ2 function in the brain and its influence on the actions of repeated eletroconvulsive shock. Neuropharmacol, 1998, 27: 1239-1248.Heal DJ, Smith SL. The effects of acute and repeated administration of T3 to mice on 5-HТ1 and 5-НТ2 function in the brain and its influence on the actions of repeated eletroconvulsive shock. Neuropharmacol, 1998, 27: 1239-1248.Smith S, Weissman N, Anderson C et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med, 2010, 363(3): 245-256.Smith S, Weissman N, Anderson C et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med, 2010, 363(3): 245-256.Chan E, He Y, Chui C et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev, 2013, 14(5): 383-92. doi: 10.1111/obr.12015.Chan E, He Y, Chui C et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev, 2013, 14(5): 383-92. doi: 10.1111/obr.12015.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм, 2016, 13(1): 36-44. DOI: http://dx.doi.org/10.14341/omet2016136-44.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм, 2016, 13(1): 36-44. DOI: http://dx.doi.org/10.14341/omet2016136-44.Вознесенская Т.Г. Расстройства пищевого поведения при ожирении и их коррекция. Ожирение и метаболизм, 2004, 2: 2-6.Вознесенская Т.Г. Расстройства пищевого поведения при ожирении и их коррекция. Ожирение и метаболизм, 2004, 2: 2-6.Писарев Д.И., Новиков О.О., Фадеева Д.А., Жилякова Е.Т., Казакова В.С., Писарева Н.А. Масс-спектрометрия: история и перспективы использования. Молодой ученый, 2012, 10: 99-104.Писарев Д.И., Новиков О.О., Фадеева Д.А., Жилякова Е.Т., Казакова В.С., Писарева Н.А. Масс-спектрометрия: история и перспективы использования. Молодой ученый, 2012, 10: 99-104.Fritz KS, Wilcox RB, Nelson JC. Quantifying spurious free T4 results attributable to thyroxine_binding proteins in serum dialysates and ultrafiltrates. Clin. Chem., 2007, 53: 985-988.Fritz KS, Wilcox RB, Nelson JC. Quantifying spurious free T4 results attributable to thyroxine_binding proteins in serum dialysates and ultrafiltrates. Clin. Chem., 2007, 53: 985-988.Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv, 2004, 4(2): 109-23. DOI: 10.1124/mi.4.2.8Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv, 2004, 4(2): 109-23. DOI: 10.1124/mi.4.2.8Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(6): 1062-73. DOI: 10.1016/j.pnpbp.2005.03.012.Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(6): 1062-73. DOI: 10.1016/j.pnpbp.2005.03.012.Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry, 2003, 54: 879-883.Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry, 2003, 54: 879-883.Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant–induced mania in bipolar disorder: Preliminary findings. Arch. Gen. Psychiatry, 2001, 58: 539-544.Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant–induced mania in bipolar disorder: Preliminary findings. Arch. Gen. Psychiatry, 2001, 58: 539-544.Hsiao DJ, Wu LS, Huang SY, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in theGNB3 gene. Pharmacogenet Genomics. 2009, 19 (9): 730-3. doi: 10.1097/FPC.0b013e3283307cf1.Hsiao DJ, Wu LS, Huang SY, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in theGNB3 gene. Pharmacogenet Genomics. 2009, 19 (9): 730-3. doi: 10.1097/FPC.0b013e3283307cf1.Kirkegaard C. The thyrotropin response to thyrotropin-releasing hormone in endogenous depression. Psychoneuroendocrinol, 1981, 6: 189-212.Kirkegaard C. The thyrotropin response to thyrotropin-releasing hormone in endogenous depression. Psychoneuroendocrinol, 1981, 6: 189-212.Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormoneinduced changes in mRNA expression in the adult rat brain. Neurosci. Lett., 2004, 365(1): 14-18.Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormoneinduced changes in mRNA expression in the adult rat brain. Neurosci. Lett., 2004, 365(1): 14-18.

The authors declare that there are no conflicts of interest present.